Online inquiry

IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1484MR)

This product GTTS-WQ1484MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD79B gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000626.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 974
UniProt ID P40259
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ1484MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10902MR IVTScrip™ mRNA-Anti-IL1A, MABp1(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MABp1
GTTS-WQ4311MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BIVV009
GTTS-WQ1496MR IVTScrip™ mRNA-Anti-CD79B, ACD79B-VCMMAE(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ACD79B-VCMMAE
GTTS-WQ8594MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ6827MR IVTScrip™ mRNA-Anti-IL3RA, DT-IL-3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DT-IL-3
GTTS-WQ3201MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ15749MR IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA VX-15
GTTS-WQ3379MR IVTScrip™ mRNA-Anti-Canlupfam CD52, AT-005(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AT-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW